9 patents currently held
25 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next term ends in Sep 2027. from the record
Of the 25 now held by other companies, 25 name Journey Medical Corporation as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Sep 2027
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2027 · Medium confidence
Also notable
Ends Jul 2030 · High confidence
Also notable
Ends Jun 2033 · High confidence
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US 9,265,725
Cited by 220 later US patents, top 1% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2027.
Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses
US 9,167,813
Cited by 69 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
Use of NK-1 Receptor Antagonists in Pruritus
US 8,906,951
Cited by 28 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Formerly held, still cited
Notable
Ends Oct 2030 · High confidence
Cited by 130 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
now held by Journey Medical Corporation
Also notable
Ends Dec 2028 · High confidence
Cited by 126 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2028. A terminal disclaimer caps this term to an earlier patent's.
now held by Journey Medical Corporation
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 27, 2027The maintenance fee for Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses (US 9,167,813) comes due Apr 27, 2027. Unpaid by Oct 27, 2027, it lapses early.
- 1 fee due Jun 15, 2027The maintenance fee for Antibiotic Kit and Composition and Uses Thereof (US 9,211,259) comes due Jun 15, 2027. Unpaid by Dec 15, 2027, it lapses early.
Recent changes
- 2 terms have ended since Aug 20, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Oleaginous Pharmaceutical and Cosmetic Foam | 5 in force | to Feb 2029 |
| Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses | 2 in force | to Jul 2030 |
| Use of NK-1 Receptor Antagonists in Pruritus | 1 in force | to Jun 2033 |
| Foamable Iodine Composition | 1 in force | to Oct 2027 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,700,076 | Penetrating Pharmaceutical Foam In force · Low confidence | In force | Low confidence | |
| US 10,117,812 | Foamable composition combining a polar solvent and a hydrophobic carrier In force · Medium confidence | In force | Medium confidence | |
| US 7,575,739 | Foamable Iodine Composition In force · High confidence | In force | High confidence | |
| US 9,265,725 | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,820,145 | Oleaginous Pharmaceutical and Cosmetic Foam In force · High confidence | In force | High confidence | |
| US 9,211,259 | Antibiotic Kit and Composition and Uses Thereof In force · Low confidence | In force | Low confidence | |
| US 9,167,813 | Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses In force · High confidence | In force | High confidence | |
| US 9,572,775 | Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams And Their Uses In force · High confidence | In force | High confidence | |
| US 8,906,951 | Use of NK-1 Receptor Antagonists in Pruritus In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 25 patents in force now held by others · 71 patents ended · 1 application pending · 20 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.